Can nirmatrelvir/ritonavir treatment shorten the duration of COVID-19 isolation?

ABSTRACT:

Background

The impact of nirmatrelvir/ritonavir treatment on shedding of viable virus in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unclear.

Methods

A prospective cohort study evaluating mildly ill COVID-19 patients was conducted. Virologic responses were compared between nirmatrelvir/ritonavir-treatment and supportive care groups. Risk factors and relevant clinical factors for shedding of viable virus were investigated.

Results

A total of 80 COVID-19 patients were enrolled and 222 sputum specimens were collected. Ten patients were dropped during follow-up, and 33 patients in the nirmatrelvir/ritonavir and 37 in the supportive care groups were compared. The median age was 67 years, and 67% were male. Clinical characteristics were similar between g

SUBMITTER: Kim H 

PROVIDER: S-EPMC9596971 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature